Autologous stem cell transplantation with in vivo purged progenitor cells shows long‐term efficacy in relapsed/refractory follicular lymphoma. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Arcaini, Luca; Morello, Lucia; Tucci, Alessandra; Rusconi, Chiara; Ladetto, Marco; Rattotti, Sara; Bonfichi, Maurizio; Bottelli, Chiara; Gabutti, Cristina; Bernasconi, Paolo; Varettoni, Marzia; Gotti, Manuel; Troletti, Daniela; Guerrera, Maria Luisa; Fiaccadori, Valeria; Sciarra, Roberta; Ferretti, Virginia Valeria; Alessandrino, Emilio Paolo; Rossi, Giuseppe; Morra, Enrica
• Is Part Of: American journal of hematology. Volume 90:Issue 3(2015:Mar.)
• Page Start: 230
• Page End: 234
• Publication Date: 2015-03
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23919
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>High‐dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long‐term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with <italic>in vivo</italic> purged progenitors cells. We report the long‐term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline‐based debulking chemotherapy, immunochemotherapy, mobilization of <italic>in vivo</italic> purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R‐COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl‐2 negative. TRM was 0%. The 5‐year PFS was 54% and the 5‐year OS was 83%. After a median f‐up of 6.7 years (range 1.5–13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of <italic>in vivo</italic> purged progenitor cells. Am. J. Hematol. 90:230–234, 2015. © 2014 Wiley Periodicals, Inc.</p> </abstract>